{
  "id": 3316541,
  "title": "Schwab SCHD draws $679M as dividend ETF climbs 2.39%",
  "url": "https://urgent.news/2026/08/25/schwab-schd-draws-679m-as-dividend-etf-climbs-2-39",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-25T17:33:00.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/schwab-schd-draws-679m-dividend-173300246.html"
  },
  "original_language": "en",
  "account": "Over a five-day period, the Schwab U.S. Dividend Equity ETF (SCHD) amassed $679.26 million in dividends, according to TipRanks. The fund's share price experienced a 2.39% increase, as outlined by the reporting source. In this timeframe, three of the fund's most significant holdings made headlines, bolstering the ongoing trend of shifting investments from growth stocks to defensive, dividend-paying securities. Notably, Merck's collaboration with Moderna on an individualized mRNA cancer vaccine, termed intismeran autogene, reached its primary objective of recurrence-free survival in combination with Keytruda in the Phase 3 INTerpath-001 melanoma trial, as per Merck's official announcement. Moderna's CEO, Stéphane Bancel, hailed the mRNA trial data as a \"pivotal moment for personalized cancer therapy.\" Furthermore, Morgan Stanley upgraded Merck's stock rating to Overweight from Equalweight and elevated its price target to $179 from $116. Similarly, UBS raised its target to $175 from $145, and Goldman Sachs increased its target to $160 from $140, all maintaining a Buy rating, as reported on Aug. 20, 2026. Additionally, a settlement concerning infant-formula litigation bolstered the stock. As of Aug. 13, 2026, Abbott constituted the largest holding in SCHD, accounting for approximately 4.78% of the fund's assets. Amgen finished a Phase 1 study evaluating two formulations of its cholesterol drug, evolocumab, and launched a Phase 3 clinical trial for its lung-cancer medication tarlatamab, according to TipRanks. The fund underwent its annual reconstitution on March 23, 2026, incorporating 25 stocks while eliminating 22 from the Dow Jones U.S. Dividend 100 Index, as reported by the Motley Fool. Notable additions included UnitedHealth Group, Procter & Gamble, Qualcomm, and Accenture. The March reconstitution led to a 8 percentage point decrease in energy exposure, reducing it from around 21% to 13%, as indicated by Seeking Alpha. Conversely, healthcare rose by 4 percentage points, and technology rose by 3, with technology's weight climbing from 11% to over 15% by early June, as noted by the Motley Fool. The March reconstitution fortified SCHD's quality screens; however, the tech weight's decline from 11% to 8.75% post-rotation demonstrates the fund's susceptibility to rapid risk profile fluctuations between reconstitutions. Still, healthcare and consumer staples remain the primary anchors of the portfolio, contributing more than 40% of SCHD's assets, according to TopDividendETFs. As of Aug. 21, 2026, SCHD has delivered a year-to-date return of approximately 30.11%, surpassing the S&P 500's 12.11% return by roughly 18 percentage points, as detailed by 24/7 Wall St. This outperformance contrasts with the fund's three-year underperformance from 2023 through 2025. The federal funds rate currently hovers between 3.50% and 3.75%, following five successive rate hikes through July 2026, as confirmed by Trading Economics data. Among the 18 Fed officials who submitted projections, nine supported an increase in the June dot plot, with Fed Chair Kevin Warsh not submitting a projection, according to the Fed's June Summary of Economic Projections. Despite this, SCHD's trailing dividend yield of approximately 3.08% remains attractive when compared to the Vanguard Dividend Appreciation ETF (VIG) at 1.69% and the iShares Core Dividend Growth ETF (DGRO) at 1.72%, as per Dividend Vision data as of July 22, 2026. The fund's price-to-earnings ratio of around 19 suggests a discount to the broader market, as per The Motley Fool. Thus, the growing interest in dividend strategies can be attributed to SCHD's value proposition. However, the rotation into defensive dividend names may not persist indefinitely. Three factors could potentially reverse this trend: the resurgence of megacap tech, concentration risk stemming from the March reconstitution, and yield compression relative to Treasury bonds. The $679 million weekly inflow signifies a broader 2026 trend of allocating funds to defensive dividend stocks, rather than a fleeting surge. SCHD's resilience relies on the Federal Reserve maintaining a hold on rates, inflation not surging, and the tech sector not regaining its dominant position. The sustainability of a dividend yield near 3% amid a 30-year Treasury offering over 5% risk-free remains an open question. The answers to these queries will likely emerge during upcoming Federal Reserve meetings, not immediate inflow data.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}